SynthesisJournal of human hypertension2026
Chronotherapy in hypertension: a systematic review and meta-analysis of antihypertensive dosing timing on cardiovascular outcomes.
Synthesis in Journal of human hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted an updated systematic review and meta-analysis comparing the effect of morning versus nighttime (evening or bedtime) administration of antihypertensive drugs on cardiovascular outcomes. We searched PubMed, Embase, and the Web of Science for studies that enrolled patients with hypertension who received medication administered in the morning or at night. A total of 42,075 patients from the five studies were included. No significant differences were observed between morning and nighttime dosing for all-cause mortality (RR 0.99, 95% CI 0.91-1.08), myocardial infarction (RR 1.14, 95% CI 0.98-1.33), major adverse cardiovascular events (RR 1.04, 95% CI 0.92-1.19), or stroke (RR 0.95, 95% CI 0.75-1.20). These findings suggest that the timing of antihypertensive administration does not significantly influence major cardiovascular outcomes. Our results align with contemporary high-quality randomized trials (TIME, BedMed) and contrast with earlier meta-analyses. Clinical trial number Not applicable as this is a systematic review per PRISMA Guidelines.
Indexed as
Identifiers
42260096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.